Skip to main content
Premium Trial:

Request an Annual Quote

Cepheid Preliminary Q4: Earnings Up, Losses Widen

NEW YORK, Jan. 29 (GenomeWeb News) - Cepheid reported preliminary fourth-quarter results today, in which revenues increased amid widened net losses.


The company, which plans to formally announce its fourth quarter earnings Feb. 17, said its revenues increased to $4.9 million for the quarter, up from $3.7 million for the same period of 2002. Net losses meanwhile increased to $4.5 million, from $3.5 million in the year-ago quarter.


Cepheid also said its product sales for 2004 would be between $42 and $46 million, and would be weighted toward the second half of the year. Net loss, it projected, would be between $10.5 and $12.5 million.


Cepheid, of Sunnyvale, Calif, did not say why it was pre-releasing earnings and forecasts.

The Scan

UCLA Team Reports Cost-Effective Liquid Biopsy Approach for Cancer Detection

The researchers report in Nature Communications that their liquid biopsy approach has high specificity in detecting all- and early-stage cancers.

Machine Learning Improves Diagnostic Accuracy of Breast Cancer MRI, Study Shows

Combining machine learning with radiologists' interpretations further increased the diagnostic accuracy of MRIs for breast cancer, a Science Translational Medicine paper finds.

Genome Damage in Neurons Triggers Alzheimer's-Linked Inflammation

Neurons harboring increased DNA double-strand breaks activate microglia to lead to neuroinflammation like that seen in Alzheimer's disease, a new Science Advances study finds.

Long COVID-19 Susceptibility Clues Contained in Blood Plasma Proteome

A longitudinal study in eBioMedicine found weeks-long blood plasma proteome shifts after SARS-CoV-2 infection, along with proteomic signatures that appeared to coincide with long Covid risk.